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Abstract
Background: Anal cancer has become one of the most common non-AIDS-defined tumors among Human
Immunodeficiency Virus-positive (HIV+) individuals, and a rise in its incidence among HIV+ Men who have Sex with
Men (MSM) has been shown, despite the introduction of Highly Active Anti-Retroviral Therapy (HAART). Human
Papillomavirus (HPV) infections are highly prevalent among HIV+ MSM and recent studies have shown high rates of
HPV-associated anal intraepithelial neoplasia (AIN) and anal cancer among this population.
Methods: In the present study we determined the prevalence and nature of HPV co-infections in the anal canal of
324 HIV+ MSM attending a high specialty medical center in Mexico City, DNA extraction and amplification with
generic primers for HPV was performed, followed by detection of specific types and co-infections with INNO-Lipa,
and identification of variants by amplification and sequencing of the E6 and LCR region of HPV 16.
Results: We found a very high prevalence of HPV infections among this cohort (86%), with more than one fourth
of them (28%) positive for type 16. Among HPV16-positive patients, European variants were the most prevalent,
followed by Asian-American ones. Among these individuals (HPV-16+), we identified co-infections with other 21
HPV types namely; 11, 51, 52, 6, 66, 68, 74, 18, 45, 35, 26, 44, 70, 53, 54, 82, 31, 33, 56, 58, 59.
Conclusions: HIV+ MSM show a very high rate of HPV infections in the anal canal and those with type 16
exhibited a multiplicity of associated types. This study emphasizes the need for an early detection of HPV infections
among HIV+ MSM in order to establish its utility to prevent anal neoplasia and cancer.
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Background
HPV are well known for their association with cervical
cancer [1], and have also been shown to play a role in the
pathogenesis of distinct squamous cell cancers, including
anal [2,3], penile [4,5], oropharyngeal [6,7] vulvar, and con-
junctival [8] cancers. Concurrent infection with HIV may
facilitate or accelerate the pathological consequences of
HPV infections. Persistent HPV infections are very fre-
quent among HIV+ MSM [9]. Anal HPV infections, which
contribute to the development of anal warts and anal can-
cer, are very common among MSM, especially HIV+ indi-
viduals [10] and HPV-associated ano-genital malignancies
occur particularly in patients with Acquired Immunodefi-
ciency Syndrome (AIDS) [11]. HIV+ MSM are at 37-fold
greater risk of invasive anal cancer. Likewise, the incidence
of anal cancer and anal intraepithelial neoplasia (AIN), the
potential precursor lesion of squamous cell carcinoma of
the anus is very high among HIV+ MSM [12] and a defin-
ite increasing trend in the incidence of anal cancer has
* Correspondence: carranca@biomedicas.unam.mx
5Unidad de Investigación Biomédica en Cáncer, Instituto de Investigaciones
Biomédicas, Universidad Nacional Autónoma de México and Instituto
Nacional de Cancerología, SSA, México D.F., Mexico
6Laboratory of Virus & Cancer Instituto Nacional de Cancerología, Av. San
Fernando No. 22, Colonia Sección XVI, México D.F., Tlalpan 14080, México
Full list of author information is available at the end of the article
© 2014 Méndez Martínez et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public
Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this
article, unless otherwise stated.
Méndez-Martínez et al. BMC Infectious Diseases 2014, 14:671
http://www.biomedcentral.com/1471-2334/14/671
been shown despite the use of Highly Active Antiretroviral
Therapy (HAART) [13].
Infections with HPV represent the most common
sexually transmitted disease worldwide. HPV is a
double-stranded DNA virus, and 160 different types of
HPV officially described have been found at mucosal or
cutaneous sites, each with a specific tissue tropism. At
least 30 of them have been identified with high predilec-
tion for the ano-genital tract. Specific types, such as 6
and 11, are classified as low-risk (LR) types because they
have been found to be associated only with benign le-
sions. In contrast, high-risk (HR) types, including most
notably 16 and 18, have been found to be associated
with both low- and high-grade anal squamous intrae-
pithelial lesions (ASIL) as well as the majority of cervical
and anal cancers [14,15].
Risk factors for the presence of anal HPV include the
presence of anal warts and a history of receptive anal
intercourse, HIV infection, and a low CD4 cell count [16].
In a Spanish cohort HR and LR HPV types were very
prevalent in the anus of HIV+ MSM (83% and 72.7%, re-
spectively), with type 16 being the most common one.
Concurrent infection with several HPV types was also
common among HIV+ MSM (58.5%) [17]. In addition,
HIV+ men have higher rates of HPV anal infection and
higher levels of HPV type 16 than HIV- men [16,18].
In a recent study in immunocompetent heterosexual
men, the incidence of overall ano-genital HPV infections
was 24.8% [19].
The anal and cervical epithelia possess similar embry-
onic origins. Histologically, columnar epithelium with a
transition zone (with increased metaplastic activity) and
a more differentiated squamous epithelium are observed.
The anal and cervical epithelia are infected by the same
types of HPV, producing similar manifestations that
range from condyloma to squamous intraepithelial le-
sions (SILs) and cancer.
The fact that multiple concurrent infections with HPV
constitute an associated morbidity among patients in-
fected with HIV has only recently been recognized [20].
In Mexico, there have been few reports describing the
prevalence of anal HPV among HIV+ MSM. In 2002, we
studied a group of 31 HIV+ MSM from Mexico City and
detected HPV in the anal canal of 74.2% of the cases;
67.7% were positive for HR HPV types (hcII test B: 16/18/
31/33/35/39/45/51/52/56/58/59/68), and 64.5% were posi-
tive for LR HPV types (hcII test A: 6/11/42/43/44) [21].
In this study, we determined the prevalence of HPV
types infecting the anal canal of HIV+ MSM and charac-
terized the type 16 variants. In addition, we characte-
rized the HPV types associated with HPV type 16 in the
anal canals of these patients.
Methods
Samples
We analyzed 324 anal exudates from HIV+ MSM pa-
tients attending the HIV Clinic at the Instituto Nacional
de Ciencias Médicas y Nutrición “Salvador Zubirán”
(INCMNSZ) in Mexico City. Patients over 18 years old,
who presented to care between August and December
2008, were invited to participate. Samples were obtained
with a cytobrush and inserted into a tube collector
containing PreservCyt. The study was approved by the
Ethics Committees of INCMNSZ SSA, and the Instituto
Nacional de Cancerología, SSA. Written informed con-
sent was obtained from all of the participants.
Data collection
Socio-demographic, clinical and sexual behavior information
was collected using a self-applied written questionnaire, with
Table 1 Demographic and Clinic characteristics of patients included
Variable Total N = 324 HPV+ N = 279 HPV- N = 45 p-value
Age 39 (33–45) 38 (32–44) 42 (35–49) 0.015
Education year 12 (10–16) 12 (10–18) 12 (10–16) 0.777
Employed 206 (64) 179 (65) 27 (59) 0.637
CD (cells/mL) 414 (267–592) 409 (267–578) 459 (287–699) 0.267
Viral Suppression 268 (83) 228 (82) 41 (91) 0.127
Time since diagnoses (years) 6.22 (2.99-9.9) 6.12 (2.80-9.47) 7.80 (4.29-12.0) 0.077
Time since treatment (years) 2.76 (0.5-6.2) 2.60 (0.50-6.00) 3.77 (0.96-7.39) 0.212
Regiment of *HAART Initiation
PI 99 (31) 88 (32) 11 (24) 0.718
NNRTI 175 (54) 148 (55) 27 (61)
Other 39 (12) 33 (12) 6 (13)
Notes: Median and Interquartile range reported for continuous variable. Number of patients and percentage reported for categorical variables. Viral suppression
defined as HIV-RNA <400 copies/mL.
*Information available only for 313 patients.
Regimens: PI Protease Inhibitor, NNRTI Non-nucleoside Reverse transcriptase Inhibitors, Other.
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assistance of one of the researchers (NR-M) who aid par-
ticipants if needed. Clinical information was verified and
completed with information available in the clinic records.
Detection and typing of HPV
Extraction and purification of DNA was performed with
the Genomics Wizard kit (PROMEGA). Polymerase
chain reaction (PCR) was performed using the MY09/11
primers, which detect a fragment from the L1 gene.
Positive samples were evaluated in a second PCR with
specific primers to detect the E6 gene of HPV type 16 or
a fragment form the LCR of HPV type 18. Negative sam-
ples underwent a second PCR using the GP5+/6+
primers, which detect a shorter fragment from the L1
gene and those positive underwent PCR reactions to de-
tect type 16 E6 gene or an LCR fragment form type 18.
Finally, all negative samples were subjected to a final
PCR to identify a fragment from the β-globin gene to
rule out problems of DNA quality or integrity. HPV type
16+ samples were subjected to a PCR to identify variants
within E6 and the long control region (LCR) with spe-
cific primers. The PCR products were sequenced using
the Big Dye terminator kit and an AB Applied Biosystems
Prism 3100. For the identification of the other viral types
present in the samples, we used the INNO-LiPA HPV
Genotyping Extra kit (INNOGENETICS), which detects
28 different HR types of HPV (16, 18, 26, 31, 33, 35, 39,
45, 51, 52, 53, 56, 58, 59, 66, 68, 73 and 82) as well as a
number of low-risk HPV genotypes (6, 11, 40, 43, 44, 54,
70) and the additional types 69, 71, and 74.
Statistical analyzes
The statistical analyzes were performed by using the
Kruskall-wallis test for continuous variables and chi-
square test and Fisher-exact test were done to compare
proportions of categorical variables.
Results
A total of 324 MSM patients attending the HIV/AIDS
Clinic at the INCMNSZ between August and December
2008 were invited and agreed to participate in this study.
The majority was young adults (39.1, SD = 9.4) years old,
educated and economically active (79.2% had more than
9 years of education, and 77.1% were employed at entry).
The mean duration of HIV infection since diagnosis
was 83 (SD = 66.4) months. Approximately 58.4% of the
participants had received a diagnosis of AIDS at some
point during the course of their HIV disease. Three hun-
dred two (92.4%) of 324 patients were being treated with
HAART; 85.1% of the patients exhibited a T lymphocyte
CD4 count above 200 cells/μl (mean = 442 cells/ ml),
and 75% exhibited <400 copies/ml of HIV-1 RNA. A sig-
nificant association was found between presence of HPV
and age. HPV- patients were older than those that were
HPV+ (Table 1).
The total prevalence of HPV in the anal canal of this
population was very high (86%; 279/324). Of the HPV+
samples, 27.5% were positive for type 16 (77/279), 8.6%
for type 18 (24/279), 36% for both types (101/279) and
64% for other HPV types (178/279). Finally, only 45
samples were found to be HPV- (13.6%) (Table 2).
Table 2 Summary of HPV
TOTAL (n) HPV (n) HPV16/HPV18* (N) HPV16-HPV18 - (N) HPV16+ (n) HPV18+ (n) HPV-
100% (324) 86.1% (279) 27.5% (89) 58.6% (190) 23.8% (77)** 7.4% (24) 13.9% (45)
Notes: *Patients were positive for HPV16 and/or HPV18. **There were 12 patients that were doubly infected by HPV type 16 and 18.
Figure 1 European variants of HPV-16 are highly prevalent among HIV+ MSM. A total of 39 clinical samples, were sequenced across the E6
(nt 104–559) and LCR (nt 7480–7843) regions to determine variant and intra-variant types. Variants and intra-variants were classified according to
Yamada et al. [23].
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In order to try to characterize HPV type 16 variants
present in this population, and due to limited resources,
39 HPV16+ samples were subjected to further analysis
by sequencing the LCR and E6 regions. Among this sub-
population, three variants of HPV type 16 were identi-
fied. The most prevalent variants (70%) were the Euro-
pean variants (E), followed by Asian American (AA)
variants (22.5%) and African (Af) variants (2.5%). Within
the European variants, we identified 7 different subclasses:
E-P in 11 samples, E-m in 2 samples, E-G131G in 2 sam-
ples, E-A176T in one sample, E-A176G in 6 samples, E-
A178T in 3 samples, and E-C188G in 5 samples. Concern-
ing the Asian American variants, we identified 2 subclasses:
AAa in 6 samples and AAc in 3 samples. Finally, an Af
variant was identified in one sample. All of these results
are summarized in Figure 1. The fact that the majority of
type HPV type 16 variants present in this population were
of the European lineage could suggest a reduced risk to de-
velop anal lesions and cancer for individuals carrying them,
as compared to individual that carry Asian-American vari-
ants, has been shown for cervical cancer [22].
In addition, we analyzed which other types of HPV were
present in this sub-population of 39 samples of HPV type
16+ individuals. The most frequent co-infecting HPV ge-
notypes were 6, 11, 44 and 70 among the low-risk types;
16, 18, 52, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, and 59
Figure 2 High and wide prevalence of high risk HPVs co-infecting the anal canal of HPV16-HIV+ MSM. Graphical representation of
different viral types found in the sample analyzed, as described in Methods. Colors indicated associated risk; Low (Green Rectangle),
High (Red Rectangle), or indeterminate (Blue Rectangle).
Figure 3 More than half of the patients have between 4 and 6 different viral types. The number of different viral types among individuals
was determined as described in Methods.
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among the high-risk types; and 66 (probable high risk),
69/71 and 74, which are currently considered indetermin-
ate risk (see Figure 2).
The distribution of the number of different HPV types
in this sub-population is shown in Figure 3. Two peaks,
one of 11 individuals with 5 different viral types and the
other with 3 individuals with 13 different types were seen.
We observed that only 5% of the 39 HPV type 16+ samples
analyzed were singly or double infected, whereas 95% of
the type 16+ samples exhibited multiple HPV infections.
Among multiply infected samples, 5% (2/39) had 3 viral
types, 13% (5/39) had 4 viral types, 28.5% (11/39) had 5
viral types, 10.25% (4/39) had 6 viral types, and 7.7% (3/39)
had 7, 8 or 13 different viral types. A detailed analysis of
the different types of HPV present in this population is
shown in Figure 4.
We performed a statistical analysis to compare clinical
variables among HPV type 16/18+ and HPV- patients and
found that age, viral suppression and time since diagnosis
were significantly different among them. HPV- patients
were older, have more HIV viral suppression and more time
since diagnosis than HPV16/18+ patients (see Table 3).
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Figure 4 Multiplicity of HPV types coinfecting the anal canal of HIV+ MSM, additional HPV type found among HPV type 16-positive
HIV+ MSM. 39 HPV type 16 positive cases were analyzed by INNO-LiPA to determine additional viral genotypes present in each sample.
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Further studies comparing the prevalence of HPV in
the oral cavity among these patients will be performed
with a follow-up that could address the prevalence of
HPV and anal lesions among this cohort of HIV+ MSM.
Discussion and conclusions
HPV has been extensively studied for its role in cervical
cancer development, but its association with anal cancer
is less well defined. This study was conducted among
HIV+ MSM attending a specialty medical center in
Mexico City. We observed a high prevalence of HPV in-
fections in the anal region, confirming previous reports
[17,18]. HR HPV types were most prevalent among a
subgroup of HPV16+ patients, similar to what has been
shown in previous studies of patients in Spain, Denmark
and Sweden [17,24]. The fact that HPV16 was the most
prevalent is in agreement with previous reports. To our
knowledge this is the first report on the presence of vari-
ants of HPV16 among HIV+ MSM.HPV16 was found in
23.8% of our patients, similar to what has been reported
previously [25]. It is known that infection with HIV in-
creases the risk of acquisition of HPV and suggests that
persistence of HPV may also be increased [24].
The high prevalence of anal HPV, particularly type 16
could considerably increase the possibility of developing
anal cancer among this population. Our results suggest
that the early detection and treatment of lesions in the
anal epithelium of these individuals may prevent anal
cancer, one of the few non–AIDS-defining malignancies.
Priority should be given to the identification and treat-
ment of anal lesions in MSM with HIV/AIDS [26].
In Mexico, few data on this type of cancer, and even
fewer with respect to the HIV+ population, have been
obtained. Here, we describe the prevalence of different
HPV types co-infecting individuals with HPV type 16,
and we identify the type 16 variants in the anal canal of
a population of HIV+ MSM.
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Table 3 Demographic and Clinic characteristics of patients between HPV negatives and patients with HPV16 and/or
HPV18
Variable HPV16/HPV18 N = 89* HPV N = 45 p-value
Age 38 (32–44) 42 (35-49 0.029
Education years 12 (10–16) 12 (11–16) 0.803
Employed 57 (65) 27 (59) 0.780
CD4(cells/mL) 354 (244–506) 459 (287–699) 0.069
Viral Suppression 68 (76) 41 (91) 0.044
Time since diagnoses (years) 4.30 (1.63-8.55) 7.80 (4.29-12.0) 0.006
Time since treatment (years) 2.11 (0.21-5.44) 3.77 (0.96-7.39) 0.090
Regimen of ** HAART Initiation
PI 36 (43) 11 (24) 0.136
NNRTI 42 (50) 27 (61)
Other 6 (7) 6 (13)
Notes: Median and Interquartile range reported for continuous variable. Number of patients and percentage reported for categorical variables. Viral suppression
defined as HIV-RNA <400 copies/mL.
*89 patients distributed as: 65 patients with HPV16, 12 patients with HPV18 and 12 patients with HPV16 and HPV18.
**Information available for 84 patients of HPV16/HPV18 and 45 or HPV-group.
Regimens: PI Protease Inhibitor, NNRTI Non-Nucleoside Reverse Transcriptase Inhibitor, Other.
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